DMT/Harmine Formulation Alters EEG Microstates in Controlled Trial

New Evidence: DMT/Harmine Alters Brain Microstates During Psychedelic Peak

A double-blind, randomized, placebo-controlled electroencephalography (EEG) study published on September 22, 2026, demonstrates that a formulation combining N,N-dimethyltryptamine (DMT) and harmine produces distinct changes in brain activity patterns compared to harmine alone or placebo. The trial, registered as NCT04716335, involved 25 healthy adult participants who received intranasal DMT with buccal harmine, harmine alone, and placebo on separate days. The primary finding is that the DMT/harmine combination led to shorter EEG microstate durations but increased the frequency and complexity of microstate occurrences, particularly near the peak of the psychedelic experience.

This result offers direct, controlled evidence that DMT/harmine modulates transient neural state sequences in ways that are both more complex and more predictable, lending empirical support to longstanding theories about psychedelics' effects on brain network dynamics.

Mechanism: Increased Neural Signal Diversity and Metastability

The DMT/harmine combination was associated with accelerated transitions between EEG microstates, more frequent switching, and higher-order Markov statistics indicating that these transitions were less random and more structured. These findings align with the "entropic brain" hypothesis, which posits that psychedelics increase neural signal diversity and metastability—features thought to underlie the subjective richness and cognitive flexibility of the psychedelic state.

Notably, the study goes beyond prior work by quantifying not just the variability of brain states but the sequence and predictability of transitions between them. This supports the idea that psychedelics do not simply induce chaos in brain activity but may organize neural dynamics into more diverse yet structured patterns. This nuance is often missed in popular accounts, which focus on increased entropy without considering the emergence of new, non-random neural order.

Implications for Clinical Trials and Therapeutic Protocols

These neurophysiological findings, while not directly impacting current legal or access frameworks, provide foundational insights for the design of future clinical trials and therapeutic interventions. By characterizing the specific neural signatures of DMT/harmine at the peak psychedelic state, researchers can develop more precise biomarkers for monitoring drug effects and individual responses in both research and clinical settings.

• Trial Design: The ability to track microstate complexity and transition predictability could inform optimal dosing schedules and session timing, potentially improving safety and efficacy in ongoing and future trials.
• Patient Selection: Understanding individual variability in neural response patterns may help identify which participants are most likely to benefit from psychedelic-assisted interventions or may be at higher risk for adverse effects.
• Translational Research: These findings may guide the development of next-generation psychedelics or combination therapies that target specific neural dynamics, rather than relying solely on subjective reports or clinical endpoints.

As a concrete example, sponsors designing Phase II or III trials of DMT-based therapies could incorporate EEG microstate analysis as a secondary outcome, enabling more objective measurement of drug effects and potentially expediting regulatory review.

Risks, Limitations, and Unknowns

While the study provides valuable mechanistic insights, several limitations and risks remain. The sample size (n=25) is modest, and all participants were healthy adults, limiting generalizability to clinical populations. The trial used an ayahuasca-inspired formulation with specific administration routes (intranasal DMT, buccal harmine), which may not reflect other dosing methods or real-world use.

Importantly, increased neural complexity and predictability do not equate to therapeutic benefit or safety. The relationship between these EEG markers and clinical outcomes—such as symptom relief in depression or PTSD—remains to be established. There is also a risk that overemphasis on neural signatures could lead to premature biomarker adoption without sufficient validation, potentially complicating regulatory pathways or misguiding clinical practice.

Looking Forward: Building a Mechanistic Bridge to Clinical Application

This study advances the field by demonstrating that DMT/harmine produces measurable, structured changes in neural dynamics during the psychedelic state, supporting key theoretical models and opening new avenues for translational research. The next steps will require larger, more diverse samples, clinical populations, and integration of neurophysiological markers with behavioral and subjective outcomes.

For researchers and trial sponsors, these findings highlight the value of incorporating advanced EEG analytics into study protocols, not only to deepen mechanistic understanding but also to inform regulatory and therapeutic strategies. As neurophysiological biomarkers become more robust, they may eventually support personalized psychedelic medicine and more targeted interventions, provided that their clinical relevance is rigorously validated.

How we research: This article was written by Dr. Alex R. Jensen, PhD (Neuroscience), reviewed by Dr. Priya Shah, MD, on 2026-09-24. Primary sources include the original OpenAlex publication and the registered clinical trial NCT04716335.